Clinical trials
Multiple Sclerosis trials in Australia
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
78 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2002 | 1 |
| 2003 | 1 |
| 2006 | 7 |
| 2007 | 6 |
| 2008 | 5 |
| 2009 | 4 |
| 2010 | 4 |
| 2011 | 4 |
| 2012 | 2 |
| 2013 | 5 |
| 2014 | 2 |
| 2015 | 2 |
| 2016 | 4 |
| 2017 | 3 |
| 2018 | 2 |
| 2019 | 1 |
| 2020 | 5 |
| 2021 | 4 |
| 2022 | 2 |
| 2023 | 2 |
| 2024 | 2 |
| 2025 | 7 |
| 2026 | 3 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 47 |
| Recruiting | 10 |
| Terminated | 9 |
| Active, not recruiting | 7 |
| Unknown status | 3 |
| Not yet recruiting | 1 |
| Suspended | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Biogen | 15 |
| Novartis Pharmaceuticals | 14 |
| Genzyme, a Sanofi Company | 4 |
| GlaxoSmithKline | 4 |
| Novartis | 4 |
| Merck KGaA, Darmstadt, Germany | 3 |
| Sanofi | 3 |
| Actelion | 2 |
| Bayer | 2 |
| Hoffmann-La Roche | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Multiple Sclerosis | 78 |
| Multiple Sclerosis, Relapsing-Remitting | 17 |
| Recurrence | 8 |
| Multiple Sclerosis, Chronic Progressive | 5 |
| Demyelinating Diseases | 3 |
| Optic Neuritis | 2 |
| Alcoholism | 1 |
| Anxiety Disorders | 1 |
| Autoimmune Diseases | 1 |
| Autoimmune Diseases of the Nervous System | 1 |
Trials
Showing 1 to 25 of 78. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.